文献速递浆细胞疾病血栓与止血

不适合移植的多发性骨髓瘤患者接受三药/四药联合治疗中的血栓栓塞事件:BENEFIT试验的事后分析

Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial.
PubMed 文献 · J Thromb Haemost · 2025-06-14

该研究为BENEFIT随机3期试验的事后分析,纳入257例65至79岁不适合移植的新诊断多发性骨髓瘤患者,接受伊沙妥昔单抗/硼替佐米/来那度胺/地塞米松或伊沙妥昔单抗/来那度胺/地塞米松治疗。全队列6个月静脉血栓栓塞累积发生率为4.8%,低剂量直接口服抗凝药组为0.8%,预防剂量肝素组为5.6%,阿司匹林组为9.8%。多因素分析显示蛋白尿≥0.44 g/L和单克隆蛋白浓度≥22 g/L与静脉血栓栓塞风险升高显著相关,低剂量直接口服抗凝药与风险降低相关。

要点

  • 全队列6个月静脉血栓栓塞累积发生率为4.8%(95%CI 2.7%-8.1%)。
  • 低剂量直接口服抗凝药组6个月累积发生率为0.8%,低于预防剂量肝素组的5.6%和阿司匹林组的9.8%。
  • 蛋白尿≥0.44 g/L(HR 5.8)和单克隆蛋白≥22 g/L(HR 4.9)与静脉血栓栓塞风险升高显著相关。

核心结论

  • 在不适合移植的新诊断多发性骨髓瘤患者中,静脉血栓栓塞的累积发生率仍然较高。
  • 直接口服抗凝药可能是预防静脉血栓栓塞最有效的选择。

研究设计与样本

  • BENEFIT随机3期试验(NCT04751877)的事后分析,纳入257例65至79岁不适合移植的新诊断多发性骨髓瘤患者。
  • 患者接受伊沙妥昔单抗/硼替佐米/来那度胺/地塞米松或伊沙妥昔单抗/来那度胺/地塞米松治疗。

主要发现

  • 全队列6个月静脉血栓栓塞累积发生率为4.8%(95%CI 2.7%-8.1%)。
  • 低剂量直接口服抗凝药组6个月累积发生率为0.8%(95%CI 0.1%-5.6%),预防剂量肝素组为5.6%(95%CI 1.9%-16.7%),阿司匹林组为9.8%(95%CI 3.9%-24.75%)。
  • 6个月后仅发生1例静脉血栓栓塞事件。
  • 最常用的血栓预防药物为直接口服抗凝药(n=127,55.2%)、低分子量肝素(n=54,23.5%)和阿司匹林(n=40,17.4%)。
  • 发生静脉血栓栓塞的患者中三分之一未接受血栓预防。

关键数值与推荐

  • 在不同血栓预防方案中,仅低剂量直接口服抗凝药与静脉血栓栓塞风险显著降低相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) events remain a major concern for patients with newly diagnosed multiple myeloma (nMM) undergoing therapy. OBJECTIVES: Evaluate the incidence and risk factors for VTE. METHODS: Post hoc analysis of the randomized phase 3 BENEFIT trial (NCT04751877) evaluating 257 patients aged 65 to 79 years with transplant-ineligible nMM who received isatuximab/bortezomib/lenalidomide/dexamethasone or isatuximab/lenalidomide/dexamethasone. RESULTS: In the whole cohort, the 6-month cumulative incidence of VTE was 4.8% (95% CI, 2.7%-8.1%), 0.8% (95% CI, 0.1%-5.6%) in patients receiving low-dose direct oral anticoagulants (DOACs) compared with 5.6% (95% CI, 1.9%-16.7%) in those who received prophylactic-dose heparin, and 9.8% (95% CI, 3.9%-24.75%) in patients receiving aspirin. Only 1 VTE occurred beyond the 6-month period. The most frequently used thromboprophylaxis agents were DOACs (n = 127, 55.2%), low-molecular-weight heparins (n = 54, 23.5%), and aspirin (n = 40, 17.4%). We noted that one-third of patients who experienced VTE had not received thromboprophylaxis. Among the different thromboprophylaxis regimens used, only low-dose DOAC was associated with a significant reduction in the risk of VTE. In multivariate analysis, proteinuria ≥ 0.44 g/L (hazard ratio [HR], 5.8; 95% CI, 1.7-26.8) and monoclonal protein concentration ≥ 22 g/L (HR, 4.9; 95% CI, 1.3-31.9) were significantly associated with an increased risk of VTE, while low-dose DOAC was associated with a decreased risk of VTE (HR, 0.13; 95% CI, 0.007-0.67). CONCLUSION: In summary, the cumulative incidence of VTE remains high in patients with transplant-ineligible nMM. DOACs could be the most effective option for preventing VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Chalayer E, Frere C, Daguenet E, et al. Thromboembolism in transplant-ineligible multiple myeloma patients on triplet/quadruplet therapy: a post hoc analysis of BENEFIT trial. J Thromb Haemost. 2025. PMID: 40523501. doi:10.1016/j.jtha.2025.06.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。